Literature DB >> 11451859

Pleuropulmonary disease due to pergolide use for restless legs syndrome.

S K Danoff1, M E Grasso, P B Terry, J A Flynn.   

Abstract

Pergolide is an ergot-derived dopamine agonist used in Parkinson's disease and, increasingly, in restless legs syndrome. We report a patient with a 2.5-year history of weight loss, pleuropulmonary fibrosis, and exudative pleural effusion that developed insidiously while taking this medication. The extensive and invasive workup that preceded the diagnosis highlights the difficulty in attributing such a process to a drug reaction. This is the second report of such a reaction to pergolide, which is one of the increasing number of ergot-derived compounds in common clinical use.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11451859     DOI: 10.1378/chest.120.1.313

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

Review 1.  Management of restless legs syndrome in patients on dialysis.

Authors:  Miklos Z Molnar; Marta Novak; Istvan Mucsi
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Sleep-related movement disorders.

Authors:  Giovanni Merlino; Gian Luigi Gigli
Journal:  Neurol Sci       Date:  2011-12-28       Impact factor: 3.307

Review 3.  Restless legs syndrome: a sensorimotor disorder of sleep/wake motor regulation.

Authors:  Wayne A Hening
Journal:  Curr Neurol Neurosci Rep       Date:  2002-03       Impact factor: 5.081

4.  Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries.

Authors:  C Trenkwalder; D Garcia-Borreguero; P Montagna; E Lainey; A W de Weerd; P Tidswell; G Saletu-Zyhlarz; W Telstad; L Ferini-Strambi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-01       Impact factor: 10.154

Review 5.  Restless legs syndrome in the older adult: diagnosis and management.

Authors:  Shawn A Milligan; Andrew L Chesson
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

6.  Pleuropulmonary Toxicity of Another Anti-Parkinson's Drug: Cabergoline.

Authors:  Yolanda Belmonte; Oriol de Fàbregues; Marta Marti; Christian Domingo
Journal:  Open Respir Med J       Date:  2009-06-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.